Stock listing

ASX:BDX BCAL Diagnostics Limited Share Price

Follow BCAL Diagnostics Limited into a list and get an email when it puts out news.

Share price · ASX:BDX

$0.06 AUD 0.00 (0.0%)

Close on Nov 20, 2026

Past year -34.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.06 – $0.06 AUDNov 20, 2026
Volume
69 sharesNov 20, 2026
Market cap
$22.12M AUDAt the close on Nov 20, 2026 · price × 368.7M shares outstanding
52-week range
$0.052 – $0.155 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$8,905 AUDMedian day 38,002 shares · 11 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
BCAL Diagnostics Limited logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:BDX · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.060.000.0%$0.06$0.06$0.0669
$0.060.000.0%$0.06$0.06$0.06840
$0.060.000.0%$0.06$0.06$0.05961,581
$0.060.000.0%$0.06$0.06$0.060
$0.06-0.001-1.6%$0.062$0.065$0.0617,209
$0.061-0.003-4.7%$0.061$0.061$0.05811,500
$0.0640.000.0%$0.064$0.064$0.0640
$0.064-0.004-5.9%$0.064$0.064$0.0645,140
$0.068+0.001+1.5%$0.068$0.069$0.06811,408
$0.067+0.002+3.1%$0.063$0.067$0.063107,339
$0.065+0.011+20.4%$0.055$0.065$0.055349,353
$0.054-0.016-22.9%$0.067$0.067$0.053329,597
$0.07-0.012-14.6%$0.07$0.07$0.077,500
$0.082-0.002-2.4%$0.082$0.082$0.082129
$0.084+0.004+5.0%$0.084$0.084$0.08448
$0.080.000.0%$0.08$0.08$0.080
$0.080.000.0%$0.08$0.08$0.083,353
$0.080.000.0%$0.08$0.08$0.080
$0.08+0.005+6.7%$0.075$0.081$0.07546,647
$0.0750.000.0%$0.075$0.075$0.07539,054
$0.075-0.003-3.8%$0.078$0.078$0.07565,286
$0.078-0.001-1.3%$0.079$0.079$0.07822,657
$0.0790.000.0%$0.082$0.082$0.0791,560
$0.0790.000.0%$0.079$0.079$0.0790
$0.0790.000.0%$0.079$0.079$0.0790
$0.079-0.001-1.3%$0.079$0.079$0.07945,129
$0.08-0.01-11.1%$0.085$0.085$0.07981,498
$0.09-0.001-1.1%$0.091$0.091$0.09882,246
$0.091+0.001+1.1%$0.09$0.091$0.0910,372
$0.090.000.0%$0.09$0.091$0.09104,931
$0.09-0.004-4.3%$0.09$0.09$0.0933,298
$0.094+0.001+1.1%$0.094$0.094$0.0931,194
$0.093+0.002+2.2%$0.09$0.093$0.09502,259
$0.091+0.004+4.6%$0.09$0.091$0.0966,163
$0.087-0.003-3.3%$0.092$0.092$0.087360,690
$0.090.000.0%$0.091$0.091$0.087721,729
$0.09+0.009+11.1%$0.083$0.09$0.083195,868
$0.081-0.004-4.7%$0.081$0.081$0.08195,228
$0.085+0.004+4.9%$0.085$0.085$0.0851,155
$0.081-0.004-4.7%$0.082$0.082$0.08231,833
$0.085+0.003+3.7%$0.082$0.085$0.08476,737
$0.0820.000.0%$0.085$0.085$0.08281,446
$0.082-0.004-4.7%$0.08$0.083$0.08269,840
$0.0860.000.0%$0.086$0.086$0.0860
$0.0860.000.0%$0.086$0.086$0.08233,423
$0.086+0.016+22.9%$0.077$0.086$0.077265,690
$0.07-0.001-1.4%$0.071$0.071$0.07125,576
$0.0710.000.0%$0.071$0.071$0.0710
$0.071-0.004-5.3%$0.074$0.074$0.07138,658
$0.075-0.001-1.3%$0.072$0.075$0.0726,995
$0.076+0.011+16.9%$0.065$0.077$0.065180,266
$0.0650.000.0%$0.065$0.065$0.0650
$0.065-0.002-3.0%$0.067$0.067$0.065203,109
$0.067-0.002-2.9%$0.07$0.07$0.06710,148
$0.0690.000.0%$0.066$0.069$0.06640,610
$0.069+0.001+1.5%$0.069$0.069$0.06914,492
$0.068+0.003+4.6%$0.065$0.068$0.06567,478
$0.065-0.001-1.5%$0.066$0.066$0.06531,785
$0.0660.000.0%$0.067$0.07$0.065183,420
$0.066+0.006+10.0%$0.065$0.066$0.06537,346
$0.06-0.002-3.2%$0.061$0.061$0.057209,586
$0.062+0.01+19.2%$0.06$0.07$0.06351,027
$0.0520.000.0%$0.052$0.052$0.0520
$0.052-0.006-10.3%$0.059$0.059$0.052157,521
$0.058+0.002+3.6%$0.058$0.058$0.05811,072
$0.0560.000.0%$0.056$0.056$0.0560
Ticker
ASX:BDX
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
ASX
Currency
AUD

What changed lately

Latest news

BCAL Position on GSS-MAP Merger

Nov 18, 2026

Closed $0.06 (0.0%) on Nov 20, 2026

Change of Director's Interest Notice

Nov 17, 2026

Closed $0.06 (0.0%) on Nov 18, 2026

GSS - Panel Receives Application

Nov 13, 2026

Closed $0.06 (0.0%) on Nov 16, 2026

Results of Meeting

Oct 18, 2026

Closed $0.079 (0.0%) on Oct 19, 2026

All BCAL Diagnostics Limited news

BCAL Diagnostics Limited on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
46 in the last 12 months · 78 in all · newest Nov 19, 2026 · oldest 2021
Decks
19 decks · latest Oct 19, 2026

Valuation

EV/sales 150× against a median of 1.8×: 10th lowest of 11 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$27.45M AUD
P/E
Loss
EV/sales
150×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
−293.0%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
Negative equity
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
BCAL Diagnostics Limited · ASX:BDXUS$14.64MUS$18.17Mn/a150×n/an/an/an/an/a
PlexBio Co., Ltd. · TPEX:6572US$15.79MUS$7.19Mn/a1.9×n/a1.8×−49.1%0.0×n/a
Biosynex SA · EURONEXT:ALBIOUS$15.37MUS$73.75Mn/a0.7×2.3×0.4×−61.1%1.9×n/a
Verici DX PLC · LSE:VRCIUS$15.25MUS$13.61Mn/a3.6×n/a2.6×−189.2%0.1×n/a
Medicon Hellas · ATHEX:MEDICUS$14.99MUS$7.66M7.7×0.4×1.9×0.7×9.8%0.0×n/a
Pharmigene, Inc. · TPEX:7595US$14.70MUS$29.38Mn/a4.8×n/a1.9×−36.5%2.2×n/a
Rhythm Biosciences Limited · ASX:RHYUS$14.05MUS$11.94Mn/a211×n/a5.8×n/a0.1×n/a
Noul Co Ltd. · KRX:376930US$14.03MUS$6.23Mn/a1.6×n/a1.1×−389.6%0.0×n/a
Telescope Innovations Corp · CSE:TELIUS$13.52MUS$12.59Mn/a2.5×n/a5.7×−56.0%0.0×1.20
LabGenomics Co., Ltd. · KRX:084650US$13.28MUS$2.59Mn/a0.0×n/a0.1×−66.5%0.1×n/a
IDT Australia Limited · ASX:IDTUS$13.09MUS$18.52Mn/a1.4×n/a1.0×−13.4%0.6×n/a
Median of the othersUS$14.38MUS$12.27M7.7×1.8×2.0×1.5×−56.0%0.1×1.20

Team and board

Officers

OfficerRole
Anne-Louise ArnettChief Executive Officer
Guy RobertsonChief Financial Officer & Company Secretary
Jayne ShawCo-Founder and Executive Chair
Kathy KoskirisDirector of Clinical Laboratory Services
Michelle BlackwellChief Product Innovation Officer

Board

DirectorRole
Jayne ShawCo-Founder and Executive Chair
David DarlingNon-Executive Director
John HurrellNon-Executive Director and Consultant
Jonathan TrollipIndependent Non-Executive Director
Mark McConnellNon-Executive Director

Events

QuarterResultsShare move
Q2 2025Aug 28, 2025−6.3%
Q4 2024Feb 27, 2025−10.0%
Q4 2022Feb 23, 20230.0%
Q2 2022Aug 29, 2022−3.8%
Q4 2021Feb 17, 2022−3.9%
Q2 2021Jul 19, 2021

Open Events

Decks

DeckKindSlidesDate
Shareholder Meeting (October 2026)Shareholder meeting19 slidesOct 19, 2026
Investor Presentation (October 2026)Investor deck14 slidesOct 6, 2026
FY2026 Earnings PresentationEarnings29 slidesSeptember 2026
20th Bioshares Biotech Summit 2026Conference18 slidesAug 6, 2026
H1 FY2026 Earnings PresentationEarnings18 slidesFebruary 2026
Shareholder Meeting (November 2025)Shareholder meeting31 slidesNovember 2025
Corporate Update (September 2025)Corporate update11 slidesSeptember 2025
Investor Presentation (March 2025)Investor deck32 slidesMar 24, 2025
Shareholder Meeting (November 2024)Shareholder meeting21 slidesNov 22, 2024
Spark+ Australian Equities Day (September 2024)Conference24 slidesSeptember 2024
All 19 decks
DeckKindSlidesDate
18th Bioshares Biotech Summit 2024Conference21 slidesJul 11, 2024
JMM & Ethica Capital - Innovation & Investment Insights (May 2024)Conference16 slidesMay 2, 2024
Investor Presentation (March 2024)Investor deck26 slidesMar 6, 2024
Shareholder Meeting (November 2023)Shareholder meeting35 slidesNov 22, 2023
Corporate Update (August 2023)Corporate update27 slidesAug 8, 2023
Investor Presentation (August 2023)Investor deck32 slidesAugust 2023
Shareholder Meeting (November 2022)Shareholder meeting22 slidesNov 30, 2022
Shareholder Meeting (November 2021)Shareholder meeting28 slidesNovember 2021
Investor Presentation (July 2021)Investor deck28 slidesJul 21, 2021

Open Decks

Financings

RaiseDate
Convertible notes
Tranche closed: A$1
Insiders: Shareholders approved the issue of 1,000,000 Convertible Notes and up to 10,367,098 Shares on conversion to a related party
Nov 18, 2026
Convertible Notes
Update: convertible
Use of proceeds: Develop and commercialise its blood-based early cancer detection portfolio and support planned activities through FY2027
Jun 29, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue182.5K21.6K3.10M2.79M718.7K275.3K442.1K258.2K242.3K
Cost of revenue717.2K579.8K113.6K20.6K7.73K3.55K14.0K
Gross profit-534.7K21.6K3.10M2.79M698.1K275.3K434.4K254.7K228.2K
Research and development4.67M1.57M4.36M4.47M1.91M664.1K466.8K205.4K251.9K
Selling, general and administrative5.13M5.12M1.64M2.35M1.87M249.0K176.9K136.9K144.3K
Operating income-9.39M-9.96M-5.45M-4.67M-3.03M-1.80M-1.14M-683.1K-704.3K
Depreciation and amortization717.2K1.00M579.8K113.6K20.6K7.73K7.73K3.55K14.0K
EBITDA-8.67M-8.96M-4.87M-4.56M-3.01M-1.79M-1.13M-679.5K-690.3K
Interest expense346.6K92.0K99.9K16.0K0005.10K5.63K
Income before tax-9.54M-7.24M-9.45M-5.06M-3.39M-1.80M-1.04M-686.5K-708.8K
Income tax-2.17M-2.63M-3.05M-2.79M-700.0K-275.0K-342.0K-256.5K-241.2K
Net income-7.37M-7.24M-6.40M-5.06M-3.39M-1.52M-696.4K-430.0K-467.6K
Earnings per share, basic-0.02-0.02-0.03-0.02-0.02-0.01-0.00-0.00-0.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents1.59M4.52M6.47M3.17M5.57M3.41M416.2K276.6K309.1K
Short-term investments04.00M
Receivables2.38M6.93K34.6K1.11K793.3K352.6K403.3K259.3K250.4K
Inventory-2.70M3.03M780.2K-403.3K-259.3K-250.4K
Current assets4.07M7.20M9.34M6.20M10.5M4.13M819.6K536.0K559.5K
Property, plant and equipment2.71M2.93M2.17M135.2K3.85K03.92K0
Total assets7.66M9.91M12.3M8.37M10.6M4.13M819.6K540.3K560.0K
Accounts payable630.7K548.4K740.2K1.58M277.2K250.7K60.0K2.06K77.6K
Current liabilities3.00M3.11M2.60M2.26M950.4K525.6K80.6K52.1K141.9K
Long-term debt4.94M122.1K400.2K00300.0K0500.0K
Total debt6.92M2.38M1.52M1.06M300.0K500.0K
Total liabilities8.49M3.69M3.68M3.16M950.4K525.6K380.6K52.1K641.9K
Shareholders' equity-826.2K6.22M8.59M5.21M9.64M3.61M438.9K488.2K-81.8K
Shares outstanding367.6M359.6M246.2M210.9M204.3M215.1M215.1M215.1M215.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-6.16M-6.14M-4.52M-6.05M-3.22M-1.21M-661.7K-525.0K-470.8K
Capital spending-459.0K-787.7K-1.15M-362.5K-4.03M-3.85K-3.81K-7.47K-14.0K
Free cash flow-6.62M-6.92M-5.67M-6.41M-7.25M-1.21M-665.5K-532.5K-484.8K
Cash from investing-1.44M-787.7K-1.15M3.64M-4.03M-3.85K-3.81K-7.47K-14.1K
Cash from financing4.66M4.97M8.97M13.2K9.41M4.20M805.0K500.0K500.0K
Share buybacks-115.0K-444.8K50.0K-621.8K4.41M505.0K500.0K0
Change in cash-2.94M-1.95M3.30M-2.40M2.16M2.99M139.6K-32.5K15.1K

Open Financials

Filings

FilingDateTypeFiled with
BCAL Position on GSS-MAP MergerNov 18, 2026Acquisition or disposalASX
Notification regarding unquoted securities - BDXNov 17, 2026Other filingsASX
Change of Director's Interest NoticeNov 17, 2026Ownership change noticeASX
BCAL Expands Breast Cancer Biomarker ProgramNov 16, 2026Operations updateASX
Notification of cessation of securities - BDXNov 13, 2026FinancingASX
Notification of cessation of securities - BDXNov 13, 2026FinancingASX
Application for quotation of securities - BDXNov 13, 2026FinancingASX
GSS - Panel Receives ApplicationNov 13, 2026Other filingsASX
Change of Director's Interest NoticeNov 10, 2026Ownership change noticeASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
All 78 filings
FilingDateTypeFiled with
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
BCAL Welcomes Dr John Melki's Appointment to GSS BoardOct 28, 2026Other filingsASX
Results of MeetingOct 18, 2026Meeting outcomeASX
AGM 2026 PresentationOct 18, 2026Meeting outcomeASX
BREASTESTplus Research Presented at Lipidomic ConferenceOct 18, 2026Operations updateASX
GSS: Response to Media Speculation & BCAL letter to GSSOct 16, 2026Other filingsASX
Letter to Genetic Signatures Ltd ShareholdersOct 14, 2026Other filingsASX
Investor Presentation - Transforming Cancer DetectionOct 5, 2026Other filingsASX
Change in substantial holdingOct 1, 2026Ownership change noticeASX
BREASTESTplus 2 clinically validatedSep 29, 2026Operations updateASX
BCAL Introduces Avantect Multi-Cancer Early Detection TestSep 22, 2026Operations updateASX
Letter to Shareholders re Annual General MeetingSep 17, 2026Meeting noticeASX
Notice of Annual General Meeting/Proxy FormSep 17, 2026Meeting noticeASX
Clarification of BCAL's Position in Relation to GSSSep 9, 2026Other filingsASX
BCAL Seeks Board Change at Genetic SignaturesSep 2, 2026Other filingsASX
Investor Presentation September 2026Sep 2, 2026ResultsASX
Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PMAug 31, 2026ResultsASX
Appendix 4E and Annual Report to shareholdersAug 28, 2026Annual reportASX
Appendix 4G and Corporate Governance StatementAug 28, 2026Other filingsASX
BCAL Takes Interest in Genetic Signatures to 18.46%Aug 25, 2026Other filingsASX
Change in Substantial Shareholder Notice for GSSAug 25, 2026Other filingsASX
Notification regarding unquoted securities - BDXAug 25, 2026Other filingsASX
BCAL Secures Funding for FY2027 UpdateAug 21, 2026FinancingASX
Notification regarding unquoted securities - BDXAug 21, 2026Other filingsASX
Proposed issue of securities - BDXAug 21, 2026FinancingASX
Bioshares Conference Investor PresentationAug 5, 2026Operations updateASX
Quarterly Activities/Appendix 4C Cash Flow ReportJul 29, 2026Quarterly reportASX
BCAL to Acquire Shares in Genetic SignaturesJul 1, 2026Acquisition or disposalASX
BCAL Secures Funding for FY2027Jun 28, 2026FinancingASX
BCAL Develops New Blood Test for Breast Cancer RecurrenceJun 17, 2026Operations updateASX
BCAL Launches Early Detection Cancer PlatformMay 19, 2026Operations updateASX
BCAL Appoints Anne-Louise Arnett as Chief Executive OfficerMay 10, 2026Management or board changeASX
BCAL Accelerates Rollout of Avantect Early Detection TestsMar 25, 2026Operations updateASX
Half Yearly Report and AccountsFeb 17, 2026Interim reportASX
Shareholder UpdateFeb 4, 2026Operations updateASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 20, 2026Quarterly reportASX
BCAL Early Cancer Detection Tests UpdateNov 18, 2025Other filingsASX
BCAL Establishes $10m Convertible Note Facility RevisedOct 19, 2025FinancingASX
BCAL Establishes $10 million Convertible Note FacilityOct 19, 2025FinancingASX
BCAL and ClearNote Partner on Early Cancer Detection TestsSep 18, 2025Operations updateASX
Appendix 4E and Annual ReportAug 29, 2025Annual reportASX
BCAL Partners with Sonic HealthcareAug 26, 2025Operations updateASX
Commercial Partnership with Cancer Care AssociatesJul 2, 2025Operations updateASX
Investor PresentationMar 24, 2025Other filingsASX
BCAL Launches Breastest Plus Generating First RevenuesMar 23, 2025Operations updateASX
NATA Accreditation ClarificationDec 12, 2024Other filingsASX
BCAL Diagnostics Receives NATA AccreditationDec 11, 2024Operations updateASX
Appendix 4E and Annual Report to ShareholdersAug 30, 2024Annual reportASX
BCAL Commences US OperationsAug 28, 2024Operations updateASX
BCAL Receives Firm Commitments to Raise $10.5 MillionJun 3, 2024FinancingASX
Reinstatement to QuotationJun 3, 2024Trading halt or suspensionASX
Suspension from QuotationMay 30, 2024Trading halt or suspensionASX
Response to ASX Price QueryMay 30, 2024Explanation requestASX
Trading HaltMay 29, 2024Trading halt or suspensionASX
Pause in TradingMay 29, 2024Trading halt or suspensionASX
Appointment of Strategic CEO to Lead Commercial LaunchMar 5, 2024Management or board changeASX
Share Purchase Plan Offer BookletAug 29, 2023FinancingASX
Preliminary Final ReportAug 29, 2023ResultsASX
$2.4m Capital Raise to Further BREASTEST CommercialisationAug 27, 2023Other filingsASX
Breakthrough Results a Major Step Towards CommercialisationAug 1, 2023Other filingsASX
BCAL Enters US Product Development Agreement with PrecionJun 28, 2022Other filingsASX
Appendix 4D & Interim ReportFeb 17, 2022Interim reportASX
7 February Announcement - Additional InformationFeb 8, 2022Other filingsASX
Recent Analysis Significantly Improves Commercial ProspectsFeb 6, 2022Other filingsASX
Dr John Hurrell Appointed Chief Executive OfficerJan 10, 2022Other filingsASX
Strong Cohort 4 Testing Data Demonstrates Value of BCAL TestNov 2, 2021Other filingsASX
Australian Clinical Studies LaunchedSep 3, 2021Other filingsASX
Market UpdateAug 17, 2021Other filingsASX

Open Filings

Cap table

Built by 6ix from BCAL Diagnostics Limited’s releases · as of Nov 18, 2026

Common shares
368,683,291
Fully diluted
368,683,291

Fully diluted

LineShares
Common shares368,683,291

Share count over time

CountShares
Nov 22, 2026368,683,291

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Jayne Shaw
Director
Buy67,685AUD 0.06AUD 4,036Nov 17, 2026
Jayne Shaw
Director
Buy72,315AUD 0.06AUD 4,258Nov 5, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Anne-Louise ArnettChief Executive Officer · Since at least May 11, 2026
David DarlingNon-Executive Director · Since at least Nov 5, 2026
Guy RobertsonChief Financial Officer & Company Secretary · Since at least Nov 5, 2026
Jayne ShawCo-Founder and Executive Chair · Since at least Sep 3, 2026
John HurrellNon-Executive Director and Consultant · Since at least Nov 5, 2026
Jonathan TrollipIndependent Non-Executive Director · Since at least Nov 5, 2026
Kathy KoskirisDirector of Clinical Laboratory Services · Since at least Nov 4, 2026
Mark McConnellNon-Executive Director · Since at least Nov 5, 2026
Michelle BlackwellChief Product Innovation Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about BCAL Diagnostics Limited.